Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 26 | 2017 | 586 | 4.750 |
Why?
|
| Tachycardia, Ventricular | 11 | 2022 | 39 | 4.480 |
Why?
|
| Atrial Fibrillation | 17 | 2022 | 555 | 3.630 |
Why?
|
| Arrhythmias, Cardiac | 13 | 2022 | 97 | 3.300 |
Why?
|
| Gene Transfer Techniques | 18 | 2017 | 263 | 2.960 |
Why?
|
| Myocardial Infarction | 8 | 2022 | 835 | 2.560 |
Why?
|
| Heart Failure | 7 | 2022 | 654 | 1.790 |
Why?
|
| Connexin 43 | 3 | 2015 | 11 | 1.500 |
Why?
|
| Swine | 15 | 2022 | 294 | 1.420 |
Why?
|
| Genetic Vectors | 13 | 2017 | 665 | 1.280 |
Why?
|
| Catheter Ablation | 6 | 2022 | 65 | 1.280 |
Why?
|
| Cicatrix | 4 | 2022 | 36 | 1.280 |
Why?
|
| Myocardium | 11 | 2022 | 189 | 1.260 |
Why?
|
| Long QT Syndrome | 5 | 2017 | 21 | 1.240 |
Why?
|
| Heart Atria | 7 | 2022 | 102 | 1.050 |
Why?
|
| Heart Conduction System | 8 | 2014 | 31 | 1.040 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2010 | 53 | 1.020 |
Why?
|
| Defibrillators, Implantable | 6 | 2010 | 62 | 1.000 |
Why?
|
| Animals | 38 | 2022 | 17698 | 0.990 |
Why?
|
| Adenoviridae | 11 | 2010 | 111 | 0.960 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 1781 | 0.950 |
Why?
|
| Atrial Remodeling | 2 | 2020 | 16 | 0.920 |
Why?
|
| Heart | 5 | 2004 | 214 | 0.900 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2019 | 26 | 0.830 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 3 | 2010 | 7 | 0.820 |
Why?
|
| Myocytes, Cardiac | 3 | 2017 | 65 | 0.800 |
Why?
|
| Electrocardiography | 9 | 2022 | 358 | 0.800 |
Why?
|
| Heart Diseases | 1 | 2022 | 168 | 0.770 |
Why?
|
| Parvovirinae | 1 | 2017 | 1 | 0.670 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2017 | 10 | 0.670 |
Why?
|
| Epigenomics | 1 | 2018 | 56 | 0.650 |
Why?
|
| Viral Tropism | 1 | 2017 | 44 | 0.640 |
Why?
|
| Gene Editing | 1 | 2020 | 237 | 0.630 |
Why?
|
| Humans | 40 | 2022 | 49600 | 0.610 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2022 | 28 | 0.600 |
Why?
|
| Heart Rate | 6 | 2008 | 263 | 0.590 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 203 | 0.590 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 269 | 0.590 |
Why?
|
| Biological Therapy | 1 | 2016 | 17 | 0.580 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 723 | 0.580 |
Why?
|
| Calcium | 3 | 2016 | 518 | 0.560 |
Why?
|
| Up-Regulation | 2 | 2016 | 349 | 0.550 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 128 | 0.550 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 3 | 2004 | 11 | 0.540 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2022 | 9 | 0.520 |
Why?
|
| Peptides | 1 | 2017 | 498 | 0.510 |
Why?
|
| Stress, Physiological | 1 | 2015 | 170 | 0.500 |
Why?
|
| Cardiac Pacing, Artificial | 7 | 2011 | 20 | 0.490 |
Why?
|
| Atrial Function, Left | 3 | 2020 | 28 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 282 | 0.470 |
Why?
|
| Connexins | 1 | 2011 | 11 | 0.450 |
Why?
|
| Heart Arrest | 3 | 2010 | 111 | 0.430 |
Why?
|
| ERG1 Potassium Channel | 4 | 2017 | 6 | 0.430 |
Why?
|
| Heart Ventricles | 3 | 2022 | 166 | 0.420 |
Why?
|
| Perfusion | 3 | 2003 | 109 | 0.420 |
Why?
|
| Action Potentials | 6 | 2015 | 87 | 0.410 |
Why?
|
| Time Factors | 8 | 2016 | 3128 | 0.380 |
Why?
|
| Myocardial Contraction | 3 | 2006 | 75 | 0.370 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 125 | 0.370 |
Why?
|
| Models, Animal | 2 | 2010 | 197 | 0.340 |
Why?
|
| Treatment Outcome | 9 | 2016 | 3888 | 0.330 |
Why?
|
| Gene Targeting | 1 | 2007 | 81 | 0.310 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 19 | 0.300 |
Why?
|
| Atrioventricular Node | 3 | 2004 | 8 | 0.300 |
Why?
|
| Cyclic GMP | 2 | 2007 | 28 | 0.290 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 98 | 0.270 |
Why?
|
| Cell Communication | 1 | 2005 | 121 | 0.270 |
Why?
|
| Sus scrofa | 4 | 2017 | 25 | 0.260 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2004 | 43 | 0.250 |
Why?
|
| Guinea Pigs | 2 | 2022 | 103 | 0.240 |
Why?
|
| Echocardiography | 3 | 2020 | 310 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2016 | 29 | 0.230 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2022 | 15 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 453 | 0.220 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2001 | 3 | 0.210 |
Why?
|
| Adenoviruses, Human | 1 | 2001 | 10 | 0.210 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 18 | 0.210 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 16 | 0.210 |
Why?
|
| Risk Factors | 5 | 2016 | 4246 | 0.210 |
Why?
|
| Electrophysiology | 3 | 2008 | 64 | 0.210 |
Why?
|
| Lymphokines | 1 | 2001 | 63 | 0.210 |
Why?
|
| Male | 12 | 2022 | 23124 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2020 | 646 | 0.210 |
Why?
|
| Transfection | 3 | 2015 | 616 | 0.210 |
Why?
|
| Rabbits | 5 | 2003 | 301 | 0.200 |
Why?
|
| Mutation | 4 | 2015 | 2187 | 0.190 |
Why?
|
| Female | 11 | 2022 | 26316 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2016 | 48 | 0.180 |
Why?
|
| Telemetry | 1 | 2019 | 22 | 0.180 |
Why?
|
| Cardiomyopathies | 3 | 2007 | 69 | 0.180 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 2 | 0.170 |
Why?
|
| Serotonin | 1 | 1998 | 68 | 0.170 |
Why?
|
| Virus Attachment | 1 | 2017 | 19 | 0.170 |
Why?
|
| Bradycardia | 2 | 2010 | 26 | 0.170 |
Why?
|
| Syncope | 2 | 2010 | 26 | 0.170 |
Why?
|
| Electric Countershock | 2 | 2010 | 42 | 0.160 |
Why?
|
| Virulence | 1 | 2017 | 174 | 0.160 |
Why?
|
| Genes, Viral | 1 | 1997 | 55 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2017 | 101 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2019 | 2681 | 0.160 |
Why?
|
| Capsid Proteins | 1 | 2017 | 85 | 0.160 |
Why?
|
| Dependovirus | 2 | 2017 | 541 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2017 | 0.150 |
Why?
|
| Genes, Reporter | 3 | 2005 | 215 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 154 | 0.150 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2015 | 1 | 0.150 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 23 | 0.150 |
Why?
|
| Aged | 8 | 2020 | 10872 | 0.140 |
Why?
|
| Random Allocation | 2 | 2014 | 193 | 0.140 |
Why?
|
| Serine | 1 | 2015 | 82 | 0.140 |
Why?
|
| Animals, Newborn | 1 | 2015 | 228 | 0.140 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 3 | 2004 | 5 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 320 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 38 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 496 | 0.130 |
Why?
|
| Phosphorylation | 1 | 2015 | 790 | 0.120 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 74 | 0.120 |
Why?
|
| Cell Line | 1 | 2017 | 1921 | 0.120 |
Why?
|
| Choroidal Neovascularization | 1 | 2013 | 24 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 53 | 0.120 |
Why?
|
| Stilbenes | 1 | 2013 | 45 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 137 | 0.110 |
Why?
|
| Sick Sinus Syndrome | 1 | 2011 | 3 | 0.110 |
Why?
|
| Sinoatrial Node | 1 | 2011 | 2 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 593 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2013 | 148 | 0.100 |
Why?
|
| Oxygen | 1 | 2011 | 233 | 0.100 |
Why?
|
| Cardiac Electrophysiology | 1 | 2009 | 1 | 0.100 |
Why?
|
| Phenotype | 2 | 2010 | 993 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 1376 | 0.090 |
Why?
|
| Tachycardia | 1 | 2008 | 22 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 64 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 1574 | 0.090 |
Why?
|
| Middle Aged | 6 | 2020 | 13449 | 0.090 |
Why?
|
| Genotype | 1 | 2010 | 589 | 0.090 |
Why?
|
| Channelopathies | 1 | 2007 | 2 | 0.080 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 211 | 0.080 |
Why?
|
| Biomarkers | 3 | 2020 | 1002 | 0.080 |
Why?
|
| Wound Healing | 1 | 2008 | 148 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 2064 | 0.080 |
Why?
|
| Endocardium | 1 | 2006 | 9 | 0.080 |
Why?
|
| Thrombomodulin | 1 | 2006 | 16 | 0.080 |
Why?
|
| Adenosine | 1 | 2007 | 70 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2005 | 241 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2007 | 115 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2007 | 148 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2005 | 16 | 0.070 |
Why?
|
| Poloxamer | 1 | 2005 | 6 | 0.070 |
Why?
|
| Trypsin | 1 | 2005 | 42 | 0.070 |
Why?
|
| Diltiazem | 1 | 2004 | 3 | 0.070 |
Why?
|
| Tensile Strength | 1 | 2005 | 35 | 0.070 |
Why?
|
| Propanolamines | 1 | 2004 | 11 | 0.070 |
Why?
|
| Digoxin | 1 | 2004 | 14 | 0.070 |
Why?
|
| Pericardium | 1 | 2005 | 24 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 148 | 0.070 |
Why?
|
| Recurrence | 2 | 2016 | 496 | 0.070 |
Why?
|
| Femoral Vein | 1 | 2004 | 19 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 102 | 0.070 |
Why?
|
| Calcium Channels, L-Type | 1 | 2004 | 23 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 49 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 40 | 0.070 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 21 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2006 | 476 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 656 | 0.060 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 36 | 0.060 |
Why?
|
| Fibrosis | 1 | 2004 | 97 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 851 | 0.060 |
Why?
|
| Apoptosis | 2 | 2011 | 979 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1500 | 0.060 |
Why?
|
| Problem-Based Learning | 1 | 2003 | 32 | 0.060 |
Why?
|
| Solutions | 1 | 2003 | 58 | 0.060 |
Why?
|
| Aging | 1 | 2009 | 680 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2004 | 387 | 0.060 |
Why?
|
| Acute Disease | 1 | 2004 | 604 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 19 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 37 | 0.060 |
Why?
|
| Rats | 2 | 2006 | 1680 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2003 | 67 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2003 | 99 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4222 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 55 | 0.050 |
Why?
|
| Purinones | 1 | 2001 | 1 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2001 | 5 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 5 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2001 | 7 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2001 | 7 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2001 | 11 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 18 | 0.050 |
Why?
|
| Adult | 4 | 2015 | 13326 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2001 | 25 | 0.050 |
Why?
|
| Sulfones | 1 | 2001 | 31 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 50 | 0.050 |
Why?
|
| Purines | 1 | 2001 | 29 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 25 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 1936 | 0.050 |
Why?
|
| Electric Conductivity | 1 | 2000 | 39 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2001 | 119 | 0.050 |
Why?
|
| Piperazines | 1 | 2001 | 87 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2020 | 114 | 0.050 |
Why?
|
| Pyridines | 1 | 2001 | 95 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 162 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2016 | 2520 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1998 | 9 | 0.040 |
Why?
|
| Bradykinin | 1 | 1998 | 9 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 173 | 0.040 |
Why?
|
| Permeability | 1 | 1998 | 42 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1998 | 40 | 0.040 |
Why?
|
| Lac Operon | 1 | 1997 | 26 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 430 | 0.040 |
Why?
|
| Mice | 2 | 2011 | 9076 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1042 | 0.040 |
Why?
|
| Luciferases | 1 | 1997 | 95 | 0.040 |
Why?
|
| Dogs | 2 | 2011 | 285 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2016 | 106 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2015 | 11 | 0.040 |
Why?
|
| ROC Curve | 1 | 2016 | 223 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2015 | 58 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2006 | 4513 | 0.040 |
Why?
|
| Adolescent | 1 | 2006 | 5317 | 0.040 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 17 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 21 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 31 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 35 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 95 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 821 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 304 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 643 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 535 | 0.030 |
Why?
|
| Headache | 1 | 2013 | 45 | 0.030 |
Why?
|
| Fever | 1 | 2013 | 65 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 153 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 1250 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 904 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2011 | 18 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 63 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 186 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 752 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1114 | 0.020 |
Why?
|
| Electrodes | 1 | 2007 | 29 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 542 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 166 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 37 | 0.020 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2004 | 2 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2004 | 13 | 0.020 |
Why?
|
| Injections | 1 | 2004 | 71 | 0.020 |
Why?
|
| Chromans | 1 | 2004 | 13 | 0.020 |
Why?
|
| Ventricular Function | 1 | 2004 | 15 | 0.020 |
Why?
|
| Heart Block | 1 | 2004 | 19 | 0.020 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 49 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2005 | 215 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 240 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2004 | 142 | 0.020 |
Why?
|
| Health Policy | 1 | 2005 | 163 | 0.020 |
Why?
|
| Health Education | 1 | 2005 | 191 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2004 | 172 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2004 | 115 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2004 | 150 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 376 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2002 | 15 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2002 | 19 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2002 | 15 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 42 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 148 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2284 | 0.010 |
Why?
|
| United States | 1 | 2007 | 6227 | 0.010 |
Why?
|